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Abstract
Background: The success rate of timely translation of genome-based technologies to commercially feasible
products/services with applicability in health care systems is significantly low. We identified both industry and
scientists neglect health policy aspects when commercializing their technology, more specifically, Public Health
Assessment Tools (PHAT) and early on involvement of decision makers through which market authorization and
reimbursements are dependent. While Technology Transfer (TT) aims to facilitate translation of ideas into products,
Health Technology Assessment, one component of PHAT, for example, facilitates translation of products/processes
into healthcare services and eventually comes up with recommendations for decision makers. We aim to propose
a new model of valorization to optimize integration of genome-based technologies into the healthcare system.
Methods: The method used to develop our model is an adapted version of the Fish Trap Model and the Basic
Design Cycle.
Results: We found although different, similarities exist between TT and PHAT. Realizing the potential of being
mutually beneficial justified our proposal of their relative parallel initiation. We observed that the Public Health
Genomics Wheel should be included in this relative parallel activity to ensure all societal/policy aspects are dealt
with preemptively by both stakeholders. On further analysis, we found out this whole process is dependent on the
Value of Information. As a result, we present our LAL (Learning Adapting Leveling) model which proposes, based
on market demand; TT and PHAT by consultation/bi-lateral communication should advocate for relevant
technologies. This can be achieved by public-private partnerships (PPPs). These widely defined PPPs create the
innovation network which is a developing, consultative/collaborative-networking platform between TT and PHAT.
This network has iterations and requires learning, assimilating and using knowledge developed and is called
absorption capacity. We hypothesize that the higher absorption capacity, higher success possibility. Our model
however does not address the phasing out of technology although we believe the same model can be used to
simultaneously phase out a technology.
Conclusions: This model proposes to facilitate optimization/decrease the timeframe of integration in healthcare. It
also helps industry and researchers to come to a strategic decision at an early stage, about technology being
developed thus, saving on resources, hence minimizing failures.
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Background
Over time we have seen enormous transition of gen-
ome-based/life science research from the lab to products
and technologies [1-3] on the market [3-6] as a result of
knowledge valorization and spin-offs [2,3,7,8]. This can
be attributed to the concept of translational research,
which is the effective translation of new knowledge,
mechanisms and techniques generated by advances in
basic science research into new approaches for preven-
tion, diagnosis and treatment of disease essential for
improving health [9]. However, we notice that the timely
translation of genome-based technologies to commer-
cially feasible products with practical applicability or
direct implementation in health care systems is quite
low [10]. This is evident by the large amount of data
present in literature [11], patents [12,13] and the market
[3,5] compared to what actually is being used in hospi-
tals [10,14]. We identify, based on our experience as
well as derivatively, three phases of translation. The first
phase includes translation from lab to industrial applica-
tion (see T1 of Khoury et al.) [15], the second phase
being from industry to market penetration [16] and the
third phase being, shift from the market to integration
in health policy (see T3 of Khoury et al.) [15]. We
believe both academia and industry focus only on one
or maximum two of the three translational phases.
In addition, methodologies in place for translation
generally focus on the first two phases or the last phase
and as per our knowledge we have not seen a combina-
tion of the three, overlaps or jumps in general. For
example, Technology Transfer (TT) mainly addresses
the first two phases mentioned above. TT is seen as an
activity of the migration of academic discoveries to use-
ful application in the development of marketable pro-
ducts or processes [17]. TT can involve several steps
from organization to organization and can have separate
offices specialized in this activity. For example, universi-
ties have a TT office or valorization center responsible
for TT activities of university research. Basically, the TT
activity initiates from an invention of an innovative idea,
through the development of the idea into a pilot to the
creation of the technology based on the idea followed by
patenting the technology in question and ends after the
technology maturation process. The maturation process
involves the return on investment and exit strategy of a
company with respect to the technology concerned. A
simplistic example can be seen from Figure 1 below
[18]. TT is the most widely used activity [1] in business
development of academic research and spin-offs [19]. It
should be noted here however, TT can be considered as
an activity, methodology, tool or technique depending
on the user. However from the objective of our paper,
we will consider this as an activity.
The most common procedures used by decision
makers (DM) and health professionals in phase three
mentioned above involve the traditional public health
evaluation instruments [20], which include Health
Needs Assessment (HNA), Health Technology Assess-
ment (HTA) and Health Impact Assessment (HIA).
HNA is a systematic method of reviewing the health
issues facing a population, leading to agreed priorities
and resource allocation that will improve health and
reduce inequalities [20]. Correspondingly, HTA is a
multidisciplinary process that summarizes information
about the medical, social, economic and ethical issues
related to the use of a health technology in a systematic,
transparent, unbiased, robust manner. Its aim is to
inform the formulation of safe, effective, health policies
that are patient focused and seek to achieve best value
[21]. This implies to interventions as well as HTA’s
involvement in appraisals. Thus, HTA is a powerful tool
to inform policy making. According to the World
Health Organization, HIA is a combination of proce-
dures, methods and tools by which a policy, program, or
project may be judged as to its potential effects on the
health of a population, and the distribution of those
effects within the population [22]. To summarize, HTA
evaluates the performance of health care technologies,
HIA assesses the effects of policies, programs or projects
on the population’s health and HNA identifies health
priorities for a given population [20]. For our conveni-
ence, we will use the term Public Health Assessment
Tools (PHAT) for the collective reference to HNA,
HTA and HIA in the text.
It becomes apparent from above, that the translational
phases 1-2 and 3 mentioned above are investigated by
two separate entities, namely, the academia-industry
infrastructure [23] and the governmental bodies respec-
tively. This is the key reason why the two operate as
separate functions. While TT aims to facilitate the
translation of ideas into products, HTA for example,
assesses the translation of products and services into
healthcare. As per content, they both seem inseparable
in the order stated, however to our knowledge have
never been connected. As a result, there is a backlog of
relevant technologies to be integrated in Public Health
and healthcare in general in a timely as well as effective
and efficient manner [10,24,25]. Even by the time a
technology is introduced in the health care system, it is
in a way deemed redundant as more effective and effi-
cient technologies become available in the market.
Redundancy is from the perspective of the potential of
existing technologies on the market compared to the
previously introduced one in the hospital. Efficiency
measures whether healthcare resources are being used
to get the best value for money [26]. Therefore,
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efficiency can be seen in terms of added value, speed
and cost, although costs can vary. According to
Ostrower [27], effectiveness has several varying defini-
tions but one of the common ones used by institutions
includes the component of ‘having an impact’. On the
other hand (clinical) effectiveness is the extent to which
specific (clinical) interventions do what they are
intended to do, i.e. maintain and improve the health of
Programs 
Figure 1 The Technology Transfer Process. The basics include the start from research and development based on market pull or push,
successfully inventing a product based on that research, patenting the product, thereby marketing and licensing and going through the
technology maturation process. Taken from the North Carolina Agricultural and Technical State University [18].
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patients securing the greatest possible health gain from
the available resources [28]. In other words, effectiveness
and also in our case, refers to the achievement of the
overall goal (the effect). We identify the non-synergy
between TT and PHAT, as the bottleneck of technologi-
cal integration in the health care.
This brings in the new field of Public Health Geno-
mics which is the responsible and effective translation of
genome-based knowledge and technologies into public
policy and health services for the benefit of population
health [29]. It is an emerging field with increased
demands of integration of genome-based innovations i.e.
genome-based knowledge and technologies, into Public
Health due to the prior’s increasing value and relevance
in the latter. Within the concept of Public Health Geno-
mics and keeping in mind the bottleneck mentioned
above, we aim to propose a new model to facilitate
valorization of genome-based technologies into the
healthcare system in real time.
The term valorization can vary depending upon the user
(say either the economist or entrepreneur). According to
the Merriam-Webster online dictionary [30], one defini-
tion of valorize states ‘to assign value or merit to’. On the
other hand, the term valorization can be defined as the
transformation of knowledge into concrete new products,
services and processes [31]. Deriving from these two defi-
nitions and keeping in mind the definition of Public
Health Genomics, valorization in Public Health Genomics
can be seen as the ‘process of realization’ of relevant added
value ‘bioproducts’ in the domain of Public Health for
benefit of the population and healthcare systems. Here we
consider realization in terms of understanding the impor-
tance, impact or potential benefit and implementing it.
The term bioproduct may have varying definitions [32,33],
here again based on the user or source. According to the
working definition submitted to the British Columbia Bio-
products Working Group [34] with the background of
agro-forestry, bioproducts are sustainable, environmentally
friendly novel products, or products satisfying novel appli-
cations and generated from renewable (living) bio-
resources based on technologically advanced eco-efficient
conversion processes. Within our scope of usage focusing
on integration of genome-based technologies/life sciences
into healthcare, we define bioproducts as sustainable novel
products or products satisfying novel health applications
derived or inspired from genome-based information or
technologies. We define a product as a system, device,
technique or process or application. Genome-based tech-
nologies encompass all -omics initially deriving from the
(Human) Genome.
Methods
The methodology we used to develop the model is
based on the Basic Design Cycle [35] and the Fish Trap
model [36] as can be seen from Figure 2 and 3 respec-
tively. The general methodologies mentioned above are
used mainly in designing products for commercial
exploitation. In our case, the methodologies have been
adapted to fit our purpose, which can be seen in Figure
4 below. We use this adapted design technique to
address a Public Health and health policy issue, the inte-
gration of genome-based technologies into healthcare in
the concept of a new model. In the subsequent para-
graphs we briefly explain the two models from which
our methodology derived from followed by the derived
methodology itself.
The Basic Design Cycle (BDC) is stated to be the most
fundamental model of designing. The intended behavior
or function of the product is the start of product design
as can be seen from Figure 2. Broad statements on the
function/properties (use) are made in order for the
designer to know what needs to be designed. In the ana-
lysis phase the problems surrounding a new product
idea are identified (also called the problem statement),
thereby criteria are formulated from general to specific
ones over iterations which the solution should satisfy.
The next step is the development of a provisional design
via the synthesis phase (combining things) [35]. This
phase is based on human creativity and is considered
the moment of externalization and description of an
idea on any form. The next phase is simulation phase
which is considered a deductive process. Simulation in
essence is forming an image of the behavior and proper-
ties of the designed product through testing, reasoning,
etc. and results in anticipation of the real properties or
conditional predictions for the new product. The next
phase is the evaluation in which the value of the design
is established. This is based on comparison of previously
mentioned set specific criteria (see Figure 2) and actual
properties in the design. The last phase is the decision
phase whether to continue or reconsider. There is the
possibility that the designer may need to return to the
analysis or synthesis with subsequent iterations and
feedback loops [35].
The Fish Trap Model (FTM) (can be considered to be
called as to catch a final solution) is a systematic process
of designing a product form. As can be seen in the Fig-
ure 3, the fish trap is illustrated in two ways, (Figure
3A) to visualize the divergence and convergence as well
as to show the occurrence of various solution types at
each level [36]. Once possible variants are created
through curiosity/possibilities, they are categorized
according to solution type. Thereafter, one or more var-
iants are chosen to be developed into a concept which
indicates a specific solution type. Again, from here more
concrete solutions are derived from the chosen variants
thus diverging again. This narrows down to one or few
options to go forth with [36].
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As can be seen from Figure 3B, the FTM is repre-
sented in a step by step or phase format. Since the
model pushes the designer to discover alternatives on 3
levels, namely topological, typological and morphologi-
cal, it is considered a systematic process as can be seen
in the figure. Following step by step Figure 3B, in order
to develop the ‘structural concept’ the ‘basic structure’
functional components need to be defined in advance
through ‘visualization of context’. One can develop or
‘generate’ multiple variants with these components that
may differ in their respective spatial placement. These
divergent are then clustered (convergence) or ‘categor-
ize’ and a representative variant are selected to be devel-
oped into a ‘structural concept’. Again, selection of
these structural concepts will be based on evaluation
criteria and need to be put into context. For the devel-
opment of a ‘formal concept’, one or more structural
concepts are taken [36]. From these selected structural
concepts, geometric constructions via sketching are
made leading to different classes of form (generate step).
These sketches are evaluated based on their viability and
categorized into groups based on form, and improve-
ments can be still made and evaluated. Thereafter, pro-
mising candidates are further developed into one or
more ‘formal concepts’. Similar to above, further materi-
alization of one or more formal concepts is done with a
diverging exploration process again looking at a detailed
level at the solution [36].
Our methodology was adapted from the above two
mentioned models. As can be seen in Figure 4 the first
phase is the problem phase derived from the concept of
the ‘problem statement’ of the analysis phase of the
Basic Design Cycle (BDC). In our model the problem
phase includes both stating the problem (statement) of
the BDC as well as identification of the intended beha-
vior or function of the product which in our case is a
framework. This phase not only deals with identifying
the problem which needs to be solved but as well as
understanding it. As a result the intended function of
the final solution is cleared from the beginning.
The next step in our methodology is the analysis
phase which is derived partly from the remainder of the
analysis phase in the BDC and the structural concept
phase of the Fish Trap Model (FTM). From the latter,
the basic functional components are taken into our ana-
lysis phase. In other words, we look at the problem and
its potential components and factors in more detail and
analyze the data. Additionally, from the BDC concept,
our analysis phase also includes developing criteria for
the analysis and can include possible iterations and
feedback.
Analysis 
Provisional design 
Expected properties 
Function 
Criteria 
Value of the design 
Approved design 
Synthesis 
Simulation 
Evaluation 
Decision 
Figure 2 The basic design cycle . The most basic design
methodology used. All design problems have one way or the other
went through this design directly/indirectly. See text for description.
Taken from Roozenburg et al. [35].
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As a result of the analysis phase several options are
generated/developed to go forward with, which we call
the idea phase and is the next step in our methodology.
The components of this phase are derived from the
synthesis phase of the BDC which is based on human
creativity (and describes the idea on any form) and the
divergence concept (several possibilities) of the FTM.
Also, from the FTM, the basic functional components
previously defined in our analysis phase are developed
into multiple variants and clustered forming a structural
concept. This step is considered the externalization of
several relevant ideas.
The concept phase is the follow-up step of the idea
phase in our methodology and is based on the
simulation step of the BDC to develop the provisional
design and is a deductive process as one or more
options are chosen from a list (in the idea phase) based
on the context it can solve. Also, the concept phase
influentially derives from the formal concept step of the
FTM which include assessing one or more structural
concepts from our idea phase as well as geometric
sketches. From these sketches through iterations and
feedback loops one final version is selected.
The above mentioned steps in our adapted methodol-
ogy (see Figure 4) in line with the BDC and the FTM,
initially quantify the data down to a single qualitative
product or in our case, a model. This is achieved
through iterations and feedback loop which include
Basic structure 
Type Sa Type Sb 
Type Fa Type Fa 
Type M 
Visualization of context 
Basic structure 
Generate 
Categorize 
Structural concept 
Generate 
Categorize 
Formal concept 
Generate 
Categorize 
Material concept 
Alternatives on topological level 
Alternatives on typological level 
Alternatives on typological level 
Criteria
Criteria
Criteria
A B 
Figure 3 The fish trap model. (A) The convergence-divergence illustration. ‘Sa and Sb’ refer to structural concept a and structural concept b
respectively. Similarly, ‘Fa and Fb’ refer to formal concept a and formal concept b respectively. ‘M’ refers to material concept. (B) the phase or
step-wise illustration of the fish trap model. See text for description. Taken from the Delft Design guide [36].
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diverging and converging of data or components. In
other words development initiates with several ideas and
through the process and feasibility analysis narrows
down from a quantity of data to one final option good
in quality. The scope of our methodology includes and
ends at the concept phase since based on the fact the
model we propose is a theoretical framework. Nonethe-
less, validation or proof of principle and evaluation are
logically the next steps although not within the scope of
this paper. Therefore we keep these two points in the
to-be final two steps of our methodology mentioned
below.
Materialization phase will be the next step of our
methodology although not utilized in the paper. This is
derived directly from the materialization phase of the
FTM and may include diverging exploration if neces-
sary. The implementation of the product or in our case
the model/framework is considered the completion of
this phase. The final to-be phase is the evaluation phase
which is a direct derivation of the decision phase of the
BDC with a modified approach to evaluate rather than
to come to a decision. However this evaluation can lead
to further adaption of the model.
Results
On further analysis, we identified that the mainly used
activity in transfer of academic knowledge to industry/
market is TT [1,19]. On the other hand, the system
used by decision makers to come to a decision regarding
implementation of technologies in the healthcare system
are the PHAT. For simplicity, we will take one example
of the PHAT, i.e. HTA with references to other compo-
nents when seemed appropriate. As known HTA is
initiated by the need and identification of technologies
which can reduce the burden of illness and through its
steps, prioritize those with importance and relevance
[37,38] and eventually come up with recommendations
for DMs. Taking into account the HTA process [37] as
can be seen in Figure 5 below, it has several steps. The
TT activity however, similar to HTA in its complexity
Problem Phase 
Analysis Phase 
Idea Phase 
Concept Phase 
Materialization Phase 
Evaluation Phase 
Quantitative 
 
Qualitative Possibilities 
Diverge 
 
 
Converge 
Feedback loop 
Figure 4 The methodology: adapted from the Fish Trap Model and the Basic Design Cycle. The first phase is called the ‘Problem phase’.
This phase deals with identifying the problem, which needs to be solved, and understanding it. The next phase is the ‘Analysis phase’. In this
phase we look at the problem in detail and analyze relevant data per se. Next comes the ‘Idea phase’. This phase derives possible solutions
based on the analysis phase coming up with the possible options, directions or ideas to proceed with and can overlap with the analysis phase.
Following the idea phase is the ‘Concept Phase’. From the list of options generated, based on merits, one or few are selected to work on further
detail or conceptualize it. Thereafter the conceptualization, the product is materialized or brought forth and implemented. This is followed by
the evaluation of the product. The whole process can have iterations and moves from a large set of options and narrows down to a single idea
to be implemented. Adapted from the Basic Design Cycle [35] and the Fish Trap Model [36].
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of dynamic steps, varies from organization to organiza-
tion. For our case we will use the simple example, given
by North Carolina Agricultural and Technical State Uni-
versity, [18] as shown in Figure 1 above. As we can see
from the Figures 1 and 5, there are quite some similari-
ties or overlaps between the two different approaches as
well as per definitions of the two seem inseparable in
the order stated.
However, after comparing Figure 1 and 5 above, it
seems that TT should move in parallel with HTA rather
than one after the other. Below are suggested relations
between the two:
1. HNA/HTA initiates with the identification of cur-
rent health needs and prioritizes accordingly. On the
other hand, TT, kick-starts with research and devel-
opment, which in part is motivated by the current
needs in the market (market pull) or creates a need
based on scientific data (market push). It should be
noted here that literature suggests a significantly
large amount of scientific data relevant and applic-
able to health [11] which is not implemented in the
same [10], therefore justifies market push in health
and medicine. The key word here being ‘need’ is the
common ground of motivation for both TT and
HNA/HTA initiation, suggesting the reason for both
of them to start in parallel unlike what their respec-
tive definitions suggestion of one after the other. In
other words, HNA and HTA identify the gaps in the
needs of healthcare technology and its subsequent
requirement of investigation respectively, and TT
capitalizes on this need.
2. It should be stressed that consultation with exter-
nal experts form a core component of HTA during
the prioritizing of relevant technologies. Generally
speaking, experts in the field develop the technology
in the TT process, and with regard to medical tech-
nologies, take feedback from the end-consumers.
3. The core component of HTA is the assessment
phase (including the economic, ethical, legal and
social implications) of the technology in question
and can also include Horizon Scanning (can be con-
sidered part of HNA and early stages of HTA) [39].
Horizon Scanning is defined as a systematic process
for objectively evaluating the status of potential ben-
efits of foreseeable technological developments based
on contemporary research and evidence [40]. It also
implies that it may be used as a type of SWOT
(Strengths, Weaknesses, Opportunities and Threats)
analysis [40]. Assessment of the feasibility of the
1. Do health needs 
assessment 
2. Prioritize health 
needs 
 
3. Identify 
technologies 
relevant to needs 
4. Prioritize 
technologies for 
assessment 
5. Identify and consult 
with external 
experts 
 
6. Define assessment 
objectives 
Define target audience 
 
7. Define specific 
research 
questions 
 
8. Literature search 
9. Synthesis of data 
analysis, 
evaluation 
 
10. Review by external 
experts 
11. Final assessment 
Editing, formatting, 
translation, 
printing 
 
12. Dissemination 
 
Figure 5 A general outline of the HTA procedure. The picture displays how HTA investigation initiates and the different steps involved
followed by dissemination or recommendation to Government officials, for example whether or not to go forward with the technology in
question in health policy implementation. Taken from the Canadian Coordinating Office for HTA [37].
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invented technology is a given in TT before patent-
ing or placing it in the market and this generally
includes SWOT analysis. This also brings forth the
HIA, where the impact of potential technology to be
used is assessed, which also related to the TT’s strat-
egy before introducing the technology concerned in
the market. It seems logical that TT should encom-
pass Horizon Scanning within the aspect of HNA
and HTA.
4. Another point is that both fields identify related
stakeholders during the process.
It is not of the reasons above that the two (PHAT and
TT) should start off together. Rather the essence of the
story lies in the fact that both separate fields can and
should benefit from each other and en-route streamline
the integration process in order to properly address the
whole innovation pipeline. Based on the authors’ experi-
ence working with, in and around the Biotech industry,
the bottleneck of technology integration is rooted in the
fact that the industry neglects the policy aspects [41]
(can include but not limited to market authorization,
reimbursement and market penetrance) of technology
which is an important factor in determining technology
use in Public Health and healthcare at the end of the
technology maturation process. Similarly, DMs only
assess existing mature technologies to cover the aspects
of current need, which results in the untimely introduc-
tion of relevant or upcoming technologies that can solve
the ‘need’ issue more effectively and efficiently. With
this flow of thought, the above mentioned points which
suggest the anonymous inter-relations between TT and
PHAT bring forth a new window of opportunity to use
these pre-existing respective setups to expand the bot-
tleneck for sustained flow of technological integration in
the healthcare system through simultaneous initiation of
these methods rather than one after the other.
Based on the above, our model should include relative
parallel initiation of TT and PHAT with a sustainable
infrastructure or network for the two to communicate
bi-laterally and mutually benefit. On further research,
we found that the Public Health Genomics Wheel
(PHGW) [42], which describes Public Health compo-
nents or areas that can be addressed by genome-based
information and technologies, seems suitable to fit in
our model. Furthermore, we identified that the Value of
Information (VOI), the amount a person is willing to
pay to come to a decision on a subject [43], seems
appropriate for our model.
As a result of our investigation, we present our model
which we call the ‘LAL Model’ as can be seen in Figure
6 below and stands for ‘Learning Adapting Leveling’. As
we know, TT is driven by either market pull or market
push and PHAT is driven by market pull. A technology
(or market) push implies that a new invention is pushed
through research and development, production and
sales functions onto the market without proper consid-
eration of whether or not it satisfies a user need [44]. In
contrast, an innovation based upon market pull has
been developed by the research and development func-
tion in response to an identified market need [44]. Also
it is known that market push can lead to market pull
and vice-versa. It should be noted here when talking in
terms of PHAT market pull is not motivated due to
commercialization although TT may recognize it in that
way, but rather by requirement or health need. How-
ever, the (market) pull or need is the common ground
which fuels both PHAT (in particular HNA/HTA) and
TT respectively. When we talk about TT, it moves from
quantitative to qualitative output. In other words,
research and development initiates with several ideas
and through the process and feasibility analysis, quanti-
fies down to a single qualitative product to be commer-
cialized. This is represented in our Figure 6 as TT being
an inverse triangle. What also can be noticed is that the
TT triangle and PHAT bar are standing in parallel, with
the prior starting a bit earlier than the latter. TT identi-
fies possibilities of commercialization via market pull/
push based on sound scientific knowledge. The initial
stages of TT start in the lab with research and develop-
ment. At this stage, the research is motivated on market
dynamics and cannot clearly identify with the PHAT’s
Health Needs Assessment; hence the reason of this kind
of leveling or kick-off.
Based on the previous common grounds identified in
the two fields, the idea of cross cutting collaboration
starting from the equal leveling of PHAT and TT (as
shown in Figure 6 above) is the next step. The starting
point is market pull. Market pull/push demonstrates the
inter-dependability of new technologies of the PHAT
pipeline (in particular HNA and HTA) with TT activity.
TT should work two-fold, using its traditional ‘opportu-
nity identifying’ needs methodology fuelled by market
demand and bi-lateral communication through evi-
dence-based advocating for relevant (or upcoming) tech-
nologies in its activity with the PHAT organizations and
DMs. This can be made possible through public-private
partnerships (PPP). According to Laane et al. [45], aca-
demics, industry (in our case the academic-industrial
complex) [23] and government join forces in PPPs to
translate basic science into marketable applications with
social and economic value. These PPPs can take differ-
ent forms as it can be on a one-on-one basis or it can
involve multiple parties (large to small medium enter-
prises) or universities to (semi) public or private
research organizations and/or involve charities and gov-
ernment. Laane et al. [45] further states that PPPs can
have physical locations or be virtual (with researchers
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from different organizations/locations) or it can be
entirely different. PPPs are considered to be collabora-
tive (partners work together contributing knowledge/
resources), precompetitive (exclusivity not an issue in
collaboration) and they are partnerships in which the
risks/rewards, funding and intellectual properties are
shared. PPPs are supposed to:
i. Bridge the gap between the academic-industrial
complex and policy makers
ii. Pool knowledge and resources
iii. Catalyze innovation through translational
research
iv. Transmit momentum and gear social/market pull
to technology push
v. Multiple investments
vi. Align academic-industrial research agendas with
social priorities
vii. Concentrate focus and mass on areas of social
priority in which the parties are strong
viii. Increase social and economic returns of basic
research
TT 
P 
 
H 
A 
T 
Lobbying            DM          PPP 
Market Push 
Market Pull 
Public Health Genomics Wheel 
Innovation Network 
Absorption 
Capacity 
Assurance 
 Policy  
 Development  Assessment 
Relevance 
Processing Exclusivity 
 Value of Information 
Figure 6 The LAL Model: Learning Adapting Leveling. The model’s core consists of two components, the TT activity and the PHAT process
(used by DMs). This model proposes bi-lateral communication, collaboration and advocating for relevant technologies during and between the
(early-mid) TT activity and PHAT process both of which are driven by market pull/push (common denominator). This is achieved possibly
through PPPs. The two components/entities (TT & PHAT) use the PHGW as a reference point to see that all policy and societal aspects are
covered. This ongoing interaction through PPPs develops the innovation network for the current and future collaborations which is a network or
platform through which common goals can be achieved. This innovation network is dependent on the VOI, i.e. the actual relevance (including
added value) of the technology in question, the exclusivity (patent, license, etc.) of the technology to be integrated including possible hindering
factors as a result, and the processing ability or understandability of user (say health professional or doctor, etc.) with respect to the technology
and its impact. Over the process, the two core components (TT and PHAT), learn and adapt from each other within the innovation network and
level out differences in approach and concept through PPPs (in essence learning-adapting-leveling) through feedback loops and iterations. This
can be achieved over multiple or repetitive PPPs. Each network has a threshold of optimal capacity for such a learning curve, which we call the
absorption capacity. The model indicates the right balance between profit and timely interventions.
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In our case PPPs also involve consultation.
The industry should get involved in the subsequent
steps of PHAT, including identifying the current and
potential future needs, assessment, impact and prioritiz-
ing among others and should involve a feedback loop
with communication two-way. This is a good strategy to
ensure flexibility and adaptability by both parties leading
to higher chances of success both commercially and pol-
icy-wise which is principle of communicating vessels.
For example, the health/market need and technology
could be identified by the industry and possibly via con-
sultation with the end users and DMs (say HNA). After
initial research and development, the industry can
approach the HTA professionals and DMs with their
proposal to fulfill the need and collaborate through the
HTA steps and vice versa. This also includes the assess-
ment of the impact the technology will have on society
(HIA) in mutual collaboration. In hindsight, this can
help covering areas critically ignored by both, the indus-
try and the health care system.
This combination brings into the picture the PHGW,
which demonstrates the integration process of Genomics
into Public Health and healthcare in general [42]. Bes-
kow et al. [42] divides Public Health tasks within three
key domains of Public Health (Genomics), viz., Assess-
ment, Policy Development and Assurance. The industry
and DMs should systematically and in parallel go
through these domains at an early stage within our
model and integrate it in their respective strategies of
product development and development of evidence-
based guidelines. This is in addition to the TT and
PHAT inter-dependability, to ensure areas to be covered
or gaps are not neglected in their technology develop-
ment and policy respectively. Thus all critical economic,
policy and societal aspects are dealt with pre-emptively
which are generally put aside. As a result, the timely as
well as effective and efficient transition of relevant tech-
nological integration in policy and the health care sys-
tem can be ensured.
As a consequence of these interactions and setups
being developed, it is important that a sustainable infra-
structure is in place which can accommodate these
interactions since the major component of our strategy
involves complex communication. Furthermore, the sta-
keholders involved should use the concept of this infra-
structure to push forward their respective agendas
within our ‘LAL Model’. Keeping in mind this infra-
structure, our model proposes to use/develop and gives
rise to the (innovation) network which is an evolving
mutual dependency system based on resource relation-
ships in which their systemic character is the outcome
of interactions, processes, procedures and institutionali-
zation. Activities within such a network involve the
creation, combination, exchange, transformation,
absorption and exploitation of resources within a wide
range of formal and informal relationships [46,47]. This
network is dependent on the VOI (Value of Informa-
tion). VOI is the maximum price one should pay for
knowing the actual value of an uncertainty before decid-
ing on a course of action [43] (see legend of Figure 6).
In our case this can be a technology or technique in
question to be integrated in health policy and health-
care. According to Oestreich [43] and adapted to our
model, the VOI is dependent on three factors, namely
relevance to the consumer, processing ability of the cur-
rent infrastructure (the innovation network-developed
through PPP between the academic-industrial complex
and government, to understand say its clinical utility or
utility in healthcare) and exclusivity to the provider
(patent for example). This is a learning process with
continued iterations and feedback loops, and requires
the ability to learn, assimilate and use knowledge devel-
oped elsewhere through a process that involves substan-
tial investments especially of an intangible nature and is
called the absorption capacity [47,48].
Discussion
Based on our model, we believe the higher the absorp-
tion capacity, the higher the possibility of success as can
be seen from Figure 7A below. The y-axis represents
the progress and development of the innovation net-
work. The numbers on this axis are percentage units of
the expansion of the innovation network with 0.1 being
10% and 0.8 being 80%. The x-axis represents time in
years which corresponds to the timeline of the TT activ-
ity. This graph in ideal situations corresponds with the
development of upcoming or new technologies. With
regard to relevant technologies already in the market,
the same can apply, however the years may be shorter.
The gradient represents the absorption capacity, which
in our case is the function of the innovation network
with respect to time which in turn in dependent on the
VOI. The threshold or optimal possibility of the absorp-
tion capacity is marked at 80% in (say) 5 years. It can
also be noticed that the absorption capacity gradient
does not start at year 0 but rather a bit later. As earlier
mentioned, the initial stages of TT start in the lab with
research and development and the research is motivated
on market dynamics and cannot clearly identify with the
PHAT’s Health Needs Assessment, which in turn is the
necessary partner (HTA) of TT, required for the expan-
sion of the innovation network. Therefore progression
cannot start at this stage. After this step, within the TT
pipeline, the innovation network becomes activated.
Below is the proposed idea of the progression:
1. Identification of the health need (market pull/
push) by industry and subsequent research and
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development. We mark this as 0% innovation
network.
2. After initial research and development, contact is
made with the relevant authorities in HNA/HTA
and policy. We consider this 10% development of
the innovation network, which starts from 0%.
3. A proposal is developed either jointly (PHAT and
industry) or individually (say academia-industry) and
it is advocated. Networking is the key here. We con-
sider this 20% development of the innovation
network.
4. Initiation of PPP of the industry with policy
through the PHAT authorities. Partnership can be in
terms of collaborations, knowledge sharing, joint
investigations, etc. This is a major milestone; there-
fore we consider this 40% capacity of the innovation
network.
5. Over time the innovation network is developed
and expanded as the industry collaborates with deci-
sion-makers through the process of the PHAT and
TT activity pipelines which can look like a pseudo-
merger. We consider this 60% network capacity.
6. Finally, the innovation network has matured
enough to integrate relevant technologies into
healthcare systems and policy in real time as a con-
sequence and evaluate the impact using HIA. We
believe the innovation network at 80% functionality
and are considered the threshold of the absorption
capacity of this apparatus.
The steps take into consideration the PHGW. The
value of 1.0 or 100% seems not feasible as this is a
learning process and there will be always room for
improvement apart from the fact that there will be
Figure 7 Absorption Capacity as a function of the innovation network and time. A hypothetical schematic representation from top
counter-clockwise of achieving threshold capacity for technological integration in (A) ideal circumstances, (B) for a newly introduced technology
in a non-existing innovation network with the network development hindered through bureaucracy and skepticism of the new infrastructure, (C)
of an already tested innovation network moving through a 2nd round of new technological introduction.
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always unforeseen internal and external developments.
This example shows emerging technology integration
via the development from a non-existent innovation net-
work being expanded. The remaining 20% is an ongoing
process with feedback loops, within the already now
developed innovation network (above 6 steps) for more
new or relevant technology integration; thus having a
dynamic absorption capacity. This would be considered
ideal in the development of the innovation network;
however, depending on the technology to be integrated
[49] the graph can and will be represented differently
for different people/organizations over time as shown in
Figure 7B and 7C below.
The involvement of various stakeholders is an essen-
tial in order for this model to work. Ideally, government
driven regulatory requirements would greatly benefit the
model by stimulating the adoption of the model for the
right reasons. PPPs, for example, act as a cog in the lar-
ger innovation system conveying momentum from one
part to the other and are best if the push is from tech-
nology and the pull is from social and market demand
[45]. As of now the right level of intervention settings
and involvement is not ideal. Currently, it is up to the
industry to voluntarily advocate and/or implement the
model in their settings to benefit. In the process, and as
the model indicates, PPPs will bolster the involvement
and perhaps future government driven regulatory
requirements. Likewise, if decision makers identify the
benefits of this model they can voluntarily indicate it to
the industry to follow suit. Either way, in realistic set-
ting, one core stakeholder has to take the initiative to
kick-start the framework. The core stakeholders to initi-
ate the model are basically the industry (including scien-
tists in other settings) and government decision-makers
including PHAT professionals. Other important stake-
holders to sustain the process are the patient groups,
hospitals and health professionals (including doctors).
It should be emphasized here that since this process
involves advocating and PPP, the model’s ultimate goal
is to benefit the end-consumer, the patient, in a timely
and effective manner, and in the process stopping the
rightful profit backlog of relevant or upcoming technol-
ogies that generally do not reach the patient. As earlier
stated, this is dependent on the relevance to the end-
consumer combined with the processing ability of the
information generated through PPP with exclusivity to
the provider. For industry, profit is primary motivation
behind innovation research in medicine or healthcare in
general. This is not wrong as long as the health of the
patient is not compromised through misguided facts of
(ir)relevant technologies diffused into the health care
apparatus thus affecting the policy-making as a whole.
This may or may not arise from market push. In order
to avoid this, the industry is encouraged to consider
ethical behavior when embarking in this model. To keep
this in check, HTA professionals and DMs should
always have a third advisor. The first being industry,
second being the HTA experts and their sources (neu-
tral or evidence-based recommendations), and the third
being a combination of neutral external experts, health-
care providers (e.g. doctors) and patient interest groups.
The reason to keep it in this order of recommendations
is to encourage the pseudo-merger of TT and PHAT.
The industry can advocate for relevant or upcoming
technologies in its pipeline based on sound scientific
data and health needs through consultation with doctors
and patients, in the PHAT pipeline. As a result, the
industry needs to positively influence the DMs and
HTA professionals to push forward the correct agenda
for timely interventions. This can be possible if the
industry communicates with the PHAT professionals
evidently, hence the first opinion. However, the PHAT
infrastructure should not compromise its own recom-
mendation. The third opinion(s) being the most impor-
tant and the motivation of the target group is self-
explanatory as it is the patient group and they aim for
improving quality of life through improving health and
reducing burden of disease.
As a result, the model promotes an ethical balance
between profit and improving health through timely and
effective interventions. It should be noted here, however,
the classical PHAT apparatus or methodology needs to
be compatible with the current trends which is not the
case at the moment. Although revised versions of HTA
like ‘core HTA’ [50] have been established, nonetheless,
they have not proven sufficient enough to solve current
issues. Therefore, a more innovative approach [51] com-
patible with our model is required, which will be our
next step of investigation. Also TT may need to adapt
to HTA as well. However, this is within the concept of
innovation networks.
A possible limitation of the model may or may not
include its lack of addressing the phasing out of an
obsolete technology. Depending upon the stakeholder
this may be of importance. Phasing out a no longer
required technology may not be of concern for an
industrial player looking to capitalize on the market
with their new technology and seems to be the general
perception based on the authors’ experience. A very
simple example can be microarrays. To our knowledge
we have never seen a microarray company phasing out
its previous best seller over a newer version (although
they phase out the production internally depending
upon demand). Rather they simultaneously sell both
until the older version fades away. Reason being at the
end of the day it boils down the amount of sales. This
phasing out of obsolete technologies rather falls on the
ears on hospital management, policy makers among
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others. For them phasing out is equally important as
phasing in a new technology. On the other hand it can
be argued that industry should pay to a certain extent
attention on phasing out obsolete technology parallel to
their diffusion of own technologies. This can probably
ensure a smooth integration process in healthcare as it
will develop a good case for integration of emerging
technologies in the healthcare and policy. Our LAL
model itself does not address this important issue rather
focuses on the phasing in or diffusion of a new technol-
ogy in healthcare and policy. Nonetheless, our hypoth-
eses is that the same model framework could be used
simultaneously while phasing in a new technology, to
phase-out an obsolete version, but still has to be experi-
mented, which is like-wise for the phasing in concept
itself.
Conclusions
The LAL model proposes to facilitate and/or speed the
valorization process of new and relevant technologies
within healthcare systems with less chances of failure
through early on involvement of stakeholders (within
TT and PHAT). The aforementioned early on involve-
ment of stakeholders can help the industry to come to
an advance decision whether or not to continue with
the developing/emerging technology or consider upgrad-
ing it before introducing it in the market. This can be
based on for example the technology’s clinical utility (is
a measure of the health care value provided by the tech-
nology) [52] among others (HTA, etc.) thus saving on
resources. Our model has potential to guide valorization
in context with integration in health policy and health-
care systems resulting in the timely as well as effective
and efficient introduction of relevant genome-based
technologies.
Valorization generally neglects the policy side, hence
the generally fewer successes of investments by Venture
Capitalists in business models targeting healthcare. This
new model proposes to bring in fresh components to
the valorization process of scientific breakthroughs not
only to the bedside but also to the healthcare system as
a whole; thus making the process more efficient in real-
time, by solving the backlog of relevant technologies in
healthcare before they become out-dated due to intro-
duction of upgraded or newer technologies. The added
value of this model is that it brings together, as per our
knowledge for the first time, two separate entities (TT
and PHAT) to early on involvement. As a result this
can benefit both health care policy and industrial profit.
It encourages a large amount of networking and com-
munication with relevant stakeholders in order to be
successful, demonstrates the inter-dependability and
parallel initiation of policy and technological innovation.
This network builds on the ongoing absorption capacity
of the apparatus through an ethical balance between
profit and timely interventions for the benefit of the
population health. In simplistic terms it is a process of
‘Learning, Adapting and Leveling’, which in essence is
the LAL model.
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